AbbVie Inc. (NEO:ABBV)

Market Cap	525.56B
Revenue (ttm)	79.55B
Net Income (ttm)	5.08B
Shares Out	n/a
EPS (ttm)	2.86
PE Ratio	103.50
Forward PE	16.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8,826
Open	30.94
Previous Close	30.70
Day's Range	30.94 - 30.94
52-Week Range	23.68 - 31.48
Beta	0.53
RSI	66.21
Earnings Date	Oct 29, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD